Open AccessDRUG USE EVALUATION OF CORTICOSTEROIDSIN SYSTEMIC LUPUS ERYTHEMATOSUS OUTPATIENTS
Author(s) -
Maria Caecilia N.Setiawati
Publication year - 2018
Publication title -
jurnal farmasi /jurnal farmasi (journal of pharmacy)
Language(s) - English
Resource type - Journals
eISSN - 2656-8950
pISSN - 2302-7436
DOI - 10.37013/jf.v1i1.57
Subject(s) - medicine , corticosteroid , drug , aspirin , osteoporosis , pharmacotherapy , gastroenterology , pharmacology
Corticosteroids was the mainstay therapy for SLE, an autoimmune chronic desease. Prolonged use of Corticosteroid caused many side effects’ risk. This study was aimed to evaluate corticosteroid drug use in SLE outpatients. This study was conducted on April 2017 to August 2017. Cross sectional design was used and presented with analytical descriptive. The result is, 192 SLE outpatients pass the inclusion criteria and 98,96% are women. Methylprednisolon per oral is the most corticosteroid used for SLE outpatients, combine with 1 other immnunsuppresant ( 65,10 %) and combine with 2 other immunsuppresant ( 8,33% ). From BMI, 26,05% subjects are overweight, perhaps because of corticosteroids side effect, such as weight gain. More than a half SLE outpatients (58,33%) get Calcium supplement and vitamin D3 as prophylactive for osteoporosis because of prolonged use of corticosteroid and 61 SLE outpatients get drug for gastrointestinal use to avoid peptic ulcer. There are 44 cases of potential corticosteroid interaction with other drug that are given together, the most are corticosteroid and aspirin interaction, on 14 patients.